|
23 Companies |
|
30 Products |
|
30 Products |
|
0 Mechanisms of Action |
|
0 Trials |
|
425 News |
|
| «123456789» |
- Tasigna (nilotinib) / Novartis, Inhibikase
Biomarker, Enrollment change: Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=0, Withdrawn, Sponsor: The Cleveland Clinic
N=66 --> 0
- Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment change: Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jan 13, 2014
P2, N=23, Terminated, Sponsor: Novartis Pharmaceuticals
N=66 --> 0 N=31 --> 23
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
New P1/2 trial: Comparative PK PD Study in PAH Patients (Fox vs. I-Neb) (clinicaltrials.gov) - Jan 8, 2014
P1/2, N=24, Recruiting, Sponsor: Bayer
- ||||| ambrisentan / Generic mfg.
Enrollment closed, Combination therapy: AMBITION: A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jan 8, 2014
P3, N=614, Active, not recruiting, Sponsor: GlaxoSmithKline
N=31 --> 23 Recruiting --> Active, not recruiting
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment closed: IBUKI: Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study (clinicaltrials.gov) - Dec 18, 2013
P3, N=20, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed: Coenzyme Q-10 and Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 18, 2013
P=N/A, N=20, Active, not recruiting, Sponsor: The Cleveland Clinic
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment open: Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003) (clinicaltrials.gov) - Dec 11, 2013
P1, N=20, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Adempas (riociguat) / Bayer, Merck (MSD)
New P3 trial: RESPITE: Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor (clinicaltrials.gov) - Dec 9, 2013
P3, N=70, Recruiting, Sponsor: Bayer
- Enrollment open: Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005) (clinicaltrials.gov) - Dec 2, 2013
P1, N=18, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment closed: SPHERA: Efficacy of Ventavis Used in Real-life Setting. (clinicaltrials.gov) - Nov 26, 2013
P=N/A, N=39, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial initiation date: Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Nov 25, 2013
P=N/A, N=93, Recruiting, Sponsor: Imperial College London
Recruiting --> Active, not recruiting Initiation date: May 2013 --> Oct 2013
- Enrollment open: Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Nov 25, 2013
P=N/A, N=93, Recruiting, Sponsor: Imperial College London
Initiation date: May 2013 --> Oct 2013 Not yet recruiting --> Recruiting
- carvedilol / Generic mfg.
Enrollment change: Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Nov 10, 2013
P1/2, N=15, Recruiting, Sponsor: Virginia Commonwealth University
Not yet recruiting --> Recruiting N=20 --> 15
- | imatinib / Generic mfg.
Enrollment closed: Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Nov 6, 2013
P3, N=20, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=20 --> 15 Recruiting --> Active, not recruiting
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment change: Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease (clinicaltrials.gov) - Nov 3, 2013
P=N/A, N=6, Completed, Sponsor: University of California, Los Angeles
Recruiting --> Active, not recruiting N=16 --> 6
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion: Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease (clinicaltrials.gov) - Nov 3, 2013
P=N/A, N=6, Completed, Sponsor: University of California, Los Angeles
N=16 --> 6 Recruiting --> Completed
- Enrollment open: NIMS- New Implantable Pump in Pulmonary Arterial Hypertension, a Safety Follow up (clinicaltrials.gov) - Oct 29, 2013
P=N/A, N=25, Recruiting, Sponsor: NordicInfu Care AB
Recruiting --> Completed Not yet recruiting --> Recruiting
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment closed, Adherence: Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System (clinicaltrials.gov) - Oct 22, 2013
P=N/A, N=50, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| imatinib / Generic mfg.
Trial completion: Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Oct 16, 2013
P2/3, N=60, Completed, Sponsor: Novartis
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial initiation date, Compliance: Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients (clinicaltrials.gov) - Oct 13, 2013
P=N/A, N=30, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Initiation date: Jun 2013 --> Sep 2013
- ||||||| Tracleer (bosentan) / J&J, Roche
Trial completion: FUTURE 3: Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Oct 8, 2013
P3, N=64, Completed, Sponsor: Actelion
Initiation date: Jun 2013 --> Sep 2013 Active, not recruiting --> Completed
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment open, Compliance: Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation (clinicaltrials.gov) - Oct 7, 2013
P=N/A, N=15, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Trial completion: Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Oct 3, 2013
P4, N=16, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New P2 trial, FDG PET: Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI. (clinicaltrials.gov) - Sep 29, 2013
P2, N=36, Not yet recruiting, Sponsor: Brigham and Women's Hospital
- ||| Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
New P3 trial: A Pharmacokinetic Substudy of the TDE-PH-304 Protocol (clinicaltrials.gov) - Sep 2, 2013
P3, N=30, Active, not recruiting, Sponsor: United Therapeutics
- | New P1 trial: Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003) (clinicaltrials.gov) - Sep 2, 2013
P1, N=20, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||| Tracleer (bosentan) / J&J, Roche
Enrollment closed, Monotherapy: Compass-2: Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Aug 29, 2013
P4, N=334, Active, not recruiting, Sponsor: Actelion
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | New P1 trial: Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005) (clinicaltrials.gov) - Aug 19, 2013
P1, N=18, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Trial termination: Measuring Blood Pressure in the Lung Circulation With Sonar Technology (Echo-Doppler) (clinicaltrials.gov) - Aug 16, 2013
P1, N=60, Terminated, Sponsor: Echosense Ltd.
Recruiting --> Active, not recruiting Recruiting --> Terminated; Low recruitment
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment open, Compliance: Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients (clinicaltrials.gov) - Aug 12, 2013
P=N/A, N=30, Recruiting, Sponsor: Bayer
Recruiting --> Terminated; Low recruitment Not yet recruiting --> Recruiting
- Trial completion: Genetic and Environmental Characteristics of Primary Pulmonary Hypertension (clinicaltrials.gov) - Aug 7, 2013
P=N/A, N=3000, Completed, Sponsor: Vanderbilt University
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment closed: (-)-Epicatechin and Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jul 28, 2013
P1, N=15, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Completed Not yet recruiting --> Active, not recruiting
- treprostinil / Generic mfg., tadalafil / Generic mfg.
Enrollment change: Treprostinil Combined With Tadalafil for Pulmonary Hypertension (clinicaltrials.gov) - Jul 17, 2013
P4, N=1, Terminated, Sponsor: Rhode Island Hospital
Not yet recruiting --> Active, not recruiting N=66 --> 1
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial termination: RESPIRE: Ventavis® Registry Protocol (clinicaltrials.gov) - Jul 15, 2013
P=N/A, N=148, Terminated, Sponsor: Actelion
N=66 --> 1 Recruiting --> Terminated; low enrollment and difficulty recruiting eligible patients in adequate time
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment change: RESPIRE: Ventavis® Registry Protocol (clinicaltrials.gov) - Jul 15, 2013
P=N/A, N=148, Terminated, Sponsor: Actelion
Recruiting --> Terminated; low enrollment and difficulty recruiting eligible patients in adequate time N=300 --> 148
- || Tyvaso (treprostinil) / United Therapeutics Corp
Enrollment change, Real-world evidence, Real-world: Tyvaso Dosing and Titration Evaluation: TyTRATE Registry (clinicaltrials.gov) - Jul 14, 2013
P=N/A, N=100, Recruiting, Sponsor: United Therapeutics
N=300 --> 148 N=300 --> 100
- ||||||| Tyvaso (treprostinil) / United Therapeutics Corp
Trial completion: TRIUMPH: Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jul 10, 2013
P3, N=235, Completed, Sponsor: United Therapeutics
N=300 --> 100 Active, not recruiting --> Completed
- Enrollment change: DACH: Smoking: a Risk Factor for Pulmonary Arterial Hypertension? (clinicaltrials.gov) - Jul 3, 2013
P=N/A, N=500, Completed, Sponsor: University of Zurich
Active, not recruiting --> Completed N=1000 --> 500
- Trial completion: DACH: Smoking: a Risk Factor for Pulmonary Arterial Hypertension? (clinicaltrials.gov) - Jul 3, 2013
P=N/A, N=500, Completed, Sponsor: University of Zurich
N=1000 --> 500 Recruiting --> Completed
- Trial withdrawal: Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=0, Withdrawn, Sponsor: Paul Farand
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=0, Withdrawn, Sponsor: Paul Farand
Not yet recruiting --> Withdrawn N=30 --> 0
- Enrollment change: RVMET: Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jun 19, 2013
P=N/A, N=80, Recruiting, Sponsor: University of Ottawa Heart Institute
N=30 --> 0 N=60 --> 80
- New P1 trial: (-)-Epicatechin and Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jun 17, 2013
P1, N=15, Active, not recruiting, Sponsor: University of California, San Francisco
- Kuvan (sapropterin) / BioMarin, Daiichi Sankyo
Enrollment change: 6R-BH4 Pulmonary Arterial Hypertension Study (clinicaltrials.gov) - Jun 16, 2013
P1, N=14, Completed, Sponsor: Vanderbilt University
N=60 --> 80 N=20 --> 14
- Kuvan (sapropterin) / BioMarin, Daiichi Sankyo
Trial completion: 6R-BH4 Pulmonary Arterial Hypertension Study (clinicaltrials.gov) - Jun 16, 2013
P1, N=14, Completed, Sponsor: Vanderbilt University
N=20 --> 14 Active, not recruiting --> Completed
- treprostinil / Generic mfg., epoprostenol intravenous / Generic mfg.
Trial termination: Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH (clinicaltrials.gov) - Jun 11, 2013
P4, N=8, Terminated, Sponsor: United Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Study closed due to limited availability of eligible subjects and competition by for enrollment by other studies
- treprostinil / Generic mfg., epoprostenol intravenous / Generic mfg.
Enrollment change: Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH (clinicaltrials.gov) - Jun 11, 2013
P4, N=8, Terminated, Sponsor: United Therapeutics
Active, not recruiting --> Terminated; Study closed due to limited availability of eligible subjects and competition by for enrollment by other studies N=10 --> 8
- ||||| Enrollment closed: Assessmet of Patients With PAH Right Ventricular Volume (clinicaltrials.gov) - Jun 2, 2013
P3, N=83, Active, not recruiting, Sponsor: VentriPoint Diagnostics Ltd.
N=10 --> 8 Recruiting --> Active, not recruiting
- ||||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment closed: GRIPHON: Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (clinicaltrials.gov) - May 27, 2013
P3, N=1156, Active, not recruiting, Sponsor: Actelion
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Tyvaso (treprostinil) / United Therapeutics Corp
Enrollment closed: Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication (clinicaltrials.gov) - May 23, 2013
P4, N=21, Active, not recruiting, Sponsor: Los Angeles Biomedical Research Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting